Restructuring, Impairment, and Related Charges, Net - Summary of Restructuring Activity (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Sep. 30, 2022	Sep. 30, 2021	Sep. 30, 2022	Sep. 30, 2021
Restructuring Reserve [Roll Forward]
Beginning balance			$ 130
Restructuring, impairment, and related charges	$ 30	$ 32	53	$ 190
Non-cash charges			(11)
Cash payments			(39)
Other			(24)
Ending balance	109		109
Operating Segments | U.S. Pharmaceutical
Restructuring Reserve [Roll Forward]
Beginning balance			11
Restructuring, impairment, and related charges	3	10	7	22
Non-cash charges			(3)
Cash payments			(3)
Other			(1)
Ending balance	11		11
Operating Segments | Prescription Technology Solutions
Restructuring Reserve [Roll Forward]
Beginning balance			3
Restructuring, impairment, and related charges	7	0	14	18
Non-cash charges			(11)
Cash payments			(3)
Other			0
Ending balance	3		3
Operating Segments | Medical-Surgical Solutions
Restructuring Reserve [Roll Forward]
Beginning balance			1
Restructuring, impairment, and related charges	1	2	2	8
Non-cash charges			0
Cash payments			(2)
Other			0
Ending balance	1		1
Operating Segments | International
Restructuring Reserve [Roll Forward]
Beginning balance			56
Restructuring, impairment, and related charges	9	1	11	61
Non-cash charges			(1)
Cash payments			(6)
Other			(24)
Ending balance	36		36
Corporate
Restructuring Reserve [Roll Forward]
Beginning balance			59
Restructuring, impairment, and related charges	10	$ 19	19	$ 81
Non-cash charges			4
Cash payments			(25)
Other			1
Ending balance	58		58
Other Current Liabilities
Restructuring Reserve [Roll Forward]
Beginning balance			58
Ending balance	60		60
Liabilities Held For Sale
Restructuring Reserve [Roll Forward]
Beginning balance			36
Ending balance	22		22
Other Accrued Liabilities, Noncurrent
Restructuring Reserve [Roll Forward]
Beginning balance			36
Ending balance	$ 27		$ 27